Outcome and prognostic factors in 110 consecutive patients with primary uterine leiomyosarcoma:A Rare Cancer Network study

被引:1
|
作者
Alessandra Franzetti Pellanda [1 ,2 ]
Berardino De Bari [1 ,3 ]
Elisabeth Deniaud-Alexandre [4 ,5 ]
Marco Krengli [6 ]
Paul Van Houtte [7 ]
Antonella Richetti [8 ,9 ]
Salvador Villà [10 ]
Hadassah Goldberg [11 ]
Ewa Szutowicz-Zielińska [12 ]
Michel Bolla [13 ]
Heidi Rutten [14 ]
Marc Van Eijkeren [15 ]
Philip Poortmans [14 ,16 ]
Guido Henke [17 ]
Yavuz Anacak [18 ]
Steve Chan [19 ]
Christine Landmann [20 ]
Carine Kirkove [21 ]
Luciano Scandolaro [22 ]
Jacques Bernier [23 ,24 ]
René-Olivier Mirimanoff [1 ]
Mahmut Ozsahin [1 ]
机构
[1] Centre Hospitalier Universitaire Vaudois (CHUV)
[2] Clinica Luganese Moncucco  3. Centre Hospitalier Régional Universitaire “Jean Minjoz”,INSERM
[3] H?pital Tenon
[4] Centre Hospitalier Départemental
[5] Università degli Studi del Piemonte Orientale e Ospedale Maggiore della Carità
[6] Institut Jules Bordet  8. Ospedale di Circolo  9. Istituto Oncologico della Svizzera Italiana,EOC 
关键词
Uterine leiomyosarcoma; prognostic factors; radiotherapy; overall survival; local control;
D O I
暂无
中图分类号
R737.33 [子宫肿瘤];
学科分类号
摘要
Objective: Primary uterine leiomyosarcomas(ULMS) are rare,and the optimal treatment is controversial.We aimed to assess the outcome and prognostic factors in a multicenter population of women treated for primary ULMS.Methods: We retrospectively collected data of 110 women treated in 19 institutions of the Rare Cancer Network(RCN).Inclusion criteria consisted of a pathology report confirming the diagnosis of ULMS,aged 18–80 years,complete International Federation of Gynecology and Obstetrics(FIGO) stage information,complete information on treatment,and a minimum follow-up of 6 months.Local control(LC) and locoregional control(LRC),overall survival(OS) and disease-free survival(DFS) rates were computed using the Kaplan-Meier method.Univariate analysis was implemented using the log rank test,and multivariate analysis using the Cox model.Results: All patients underwent surgery.Seventy-five patients(68%) received adjuvant radiotherapy(RT),including brachytherapy in 18(16%).Seventeen patients(15%) received adjuvant chemotherapy.Median follow-up was 58(range,6–240) months.Five-year OS and DFS rates were 50% and 34%,and LC and LRC rates were 88%and 72%,respectively.On multivariate analysis,independent favorable prognostic factors were younger age,FIGO stage I,small tumor size,previous uterine disease,and no vascular invasion for OS and DFS.FIGO stage was the only favorable factor influencing LRC.Adjuvant local or systemic treatments did not improve the outcomes.Eight patients treated with RT presented a grade 3 acute toxicity,and only one patient with grade 3 late toxicity.Conclusions: In this large population of primary ULMS patients,we found good results in terms of LC and LRC.Nevertheless,OS remains poor,mainly due to the occurrence of distant metastases.An early diagnosis seemed to improve the prognosis of the patients.Adjuvant local or systemic treatments,or more aggressive surgicalprocedures such as the Wertheim procedure,did not seem to impact the outcome.
引用
收藏
页码:521 / 532
页数:12
相关论文
共 50 条
  • [41] Prognostic factors in patients with uterine leiomyosarcoma: A multiinstitutional retrospective study from the Japanese gynecologic oncology group
    Takehara, K.
    Yamashita, N.
    Motohashi, T.
    Harano, K.
    Nakanishi, T.
    Tokunaga, H.
    Susumu, N.
    Ueda, Y.
    Yokoyama, Y.
    Watanabe, Y.
    Watanabe, R.
    Teramoto, N.
    Tsuda, H.
    Saito, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [42] Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma - a multicenter study
    Bekos, Christine
    Grimm, Christoph
    Brodowicz, Thomas
    Petru, Edgar
    Hefler, Lukas
    Reimer, Daniel
    Koch, Horst
    Reinthaller, Alexander
    Polterauer, Stephan
    Polterauer, Mariella
    SCIENTIFIC REPORTS, 2017, 7
  • [43] PROGNOSTIC ROLE OF PLASMA FIBRINOGEN IN PATIENTS WITH UTERINE LEIOMYOSARCOMA - A MULTICENTER STUDY
    Bekos, C.
    Petru, E.
    Hefler, L.
    Reimer, D.
    Koch, H.
    Polterauer, S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1299 - 1299
  • [44] Prognostic role of plasma fibrinogen in patients with uterine leiomyosarcoma – a multicenter study
    Christine Bekos
    Christoph Grimm
    Thomas Brodowicz
    Edgar Petru
    Lukas Hefler
    Daniel Reimer
    Horst Koch
    Alexander Reinthaller
    Stephan Polterauer
    Mariella Polterauer
    Scientific Reports, 7
  • [45] Clinical Features and Prognostic Factors in Patients With Uterine Leiomyosarcoma: A Single-Center Experience
    Yalciner, Merih
    Bolek, Hatice
    Koksoy, Elif Berna
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [46] Impact of adjuvant treatment and prognostic factors in stage I uterine leiomyosarcoma patients treated in Commission on Cancer®-accredited facilities
    Vaz, Jennifer
    Tian, Chunqiao
    Richardson, Michael T.
    Chan, John K.
    Mysona, David
    Rao, Uma N.
    Powell, Matthew A.
    Shriver, Craig D.
    Hamilton, Chad A.
    Casablanca, Yovanni
    Maxwell, G. Larry
    Darcy, Kathleen M.
    GYNECOLOGIC ONCOLOGY, 2020, 157 (01) : 121 - 130
  • [47] Prognostic factors in solitary plasmacytoma of the bone: a multicenter Rare Cancer Network study
    David Knobel
    Abderrahim Zouhair
    Richard W Tsang
    Philip Poortmans
    Yazid Belkacémi
    Michel Bolla
    Fazilet Dinçbas Oner
    Christine Landmann
    Bernard Castelain
    Mahmut Ozsahin
    BMC Cancer, 6
  • [48] Prognostic factors in solitary plasmacytoma of the bone:: a multicenter Rare Cancer Network study
    Knobel, D
    Zouhair, A
    Tsang, RW
    Poortmans, P
    Belkacémi, Y
    Bolla, M
    Oner, FD
    Landmann, C
    Castelain, B
    Ozsahin, M
    BMC CANCER, 2006, 6 (1)
  • [49] Prognostic factors and survival outcomes of women with uterine leiomyosarcoma: A Turkish Uterine Sarcoma Group Study-003
    Ayhan, Ali
    Gungorduk, Kemal
    Khatib, Ghanim
    Cuylan, Zeliha Firat
    Boran, Nurettin
    Gokcu, Mehmet
    Celik, Husnu
    Ozgul, Nejat
    Akbayir, Ozgur
    Simsek, Tayup
    Bakay, Abdulkadir
    Kose, Mehmet Faruk
    Tunc, Mehmet
    Gulec, Umran Kucukgoz
    Koc, Sevgi
    Kuscu, Esra
    Vardar, Mehmet Ali
    Akilli, Huseyin
    Taskiran, Cagatay
    Meydanli, Mehmet Mutlu
    CURRENT PROBLEMS IN CANCER, 2021, 45 (05)
  • [50] Outcome and prognosticators in adult patients with medulloblastoma: a Rare Cancer Network study
    Atalar, B.
    Ozsahin, M.
    Call, J.
    Napieralska, A.
    Kamer, S.
    Salvador, V.
    Erpolat, P.
    Negretti, L.
    Ramstad, Y. L.
    Onal, C.
    Akyurek, S.
    Ugurluer, G.
    Baumert, B.
    Servagi-Vernat, S.
    Miller, R. C.
    Ozyar, E.
    Sio, T.
    RADIOTHERAPY AND ONCOLOGY, 2016, 119 : S159 - S160